Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

1.

Clinical outcomes after conservative management of cervical intraepithelial neoplasia grade 2 (CIN2) in women ages 21-39 years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Feb 5. pii: canprevres.0293.2017. doi: 10.1158/1940-6207.CAPR-17-0293. [Epub ahead of print]

PMID:
29437696
2.

Human Papillomavirus DNA methylation as a biomarker for cervical precancer: Consistency across 12 genotypes and potential impact on management of HPV-positive women.

Clarke MA, Gradíssimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, Lorey T, Poitras NE, Raine-Bennett T, Castle PE, Wentzensen N, Burk RD.

Clin Cancer Res. 2018 Feb 2. pii: clincanres.3251.2017. doi: 10.1158/1078-0432.CCR-17-3251. [Epub ahead of print]

PMID:
29420222
3.

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.

BMJ Open. 2018 Jan 26;8(1):e016700. doi: 10.1136/bmjopen-2017-016700.

4.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Jan 22:JCO2017753442. doi: 10.1200/JCO.2017.75.3442. [Epub ahead of print]

PMID:
29356609
5.

Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions.

Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, Furre IE, Johansson MJ, Tropé A, Sjøborg KD, Castle PE, Nygård M.

J Clin Virol. 2018 Feb - Mar;99-100:22-30. doi: 10.1016/j.jcv.2017.12.008. Epub 2017 Dec 21.

6.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, Castle PE.

Prev Med. 2017 Dec 27;109:44-50. doi: 10.1016/j.ypmed.2017.12.023. [Epub ahead of print]

PMID:
29288782
7.

Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis.

Taxa L, Jeronimo J, Alonzo TA, Gage J, Castle PE, Cremer ML, Felix JC.

J Low Genit Tract Dis. 2018 Jan;22(1):27-30. doi: 10.1097/LGT.0000000000000355.

PMID:
29271853
8.

A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix.

Castle PE, Pierz A, Stoler MH.

Gynecol Oncol. 2018 Feb;148(2):422-429. doi: 10.1016/j.ygyno.2017.12.001. Epub 2017 Dec 14. Review.

PMID:
29248196
9.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2017 Dec 6. pii: S0091-7435(17)30482-6. doi: 10.1016/j.ypmed.2017.12.004. [Epub ahead of print]

10.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
11.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2017 Nov 14. doi: 10.1093/jnci/djx225. [Epub ahead of print]

PMID:
29145648
12.

Anal Cancer Risk Among People With HIV Infection in the United States.

Colón-López V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, Pfeiffer RM, Engels EA.

J Clin Oncol. 2018 Jan 1;36(1):68-75. doi: 10.1200/JCO.2017.74.9291. Epub 2017 Nov 15.

13.

Smoking and subsequent human papillomavirus infection: a mediation analysis.

Eldridge RC, Pawlita M, Wilson L, Castle PE, Waterboer T, Gravitt PE, Schiffman M, Wentzensen N.

Ann Epidemiol. 2017 Nov;27(11):724-730.e1. doi: 10.1016/j.annepidem.2017.10.004. Epub 2017 Oct 17.

PMID:
29107447
14.

Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Jeronimo J, Castle PE, Temin S, Denny L, Gupta V, Kim JJ, Luciani S, Murokora D, Ngoma T, Qiao Y, Quinn M, Sankaranarayanan R, Sasieni P, Schmeler KM, Shastri SS.

J Glob Oncol. 2016 Oct 12;3(5):635-657. doi: 10.1200/JGO.2016.006577. eCollection 2017 Oct.

15.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2017 Oct;21(4):261-267. doi: 10.1097/LGT.0000000000000343.

16.

Correspondence regarding Suba et al., human papillomavirus screening for low and middle-income countries.

Castle PE.

Prev Med. 2017 Dec;105:356. doi: 10.1016/j.ypmed.2017.06.030. Epub 2017 Sep 19. No abstract available.

PMID:
28939142
17.

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.

PLoS Med. 2017 Sep 19;14(9):e1002388. doi: 10.1371/journal.pmed.1002388. eCollection 2017 Sep.

18.

HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.

Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L, Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M.

Cell. 2017 Sep 7;170(6):1164-1174.e6. doi: 10.1016/j.cell.2017.08.001.

PMID:
28886384
19.

The Cost-Effectiveness of Visual Triage of Human Papillomavirus-Positive Women in Three Low- and Middle-Income Countries.

Campos NG, Jeronimo J, Tsu V, Castle PE, Mvundura M, Kim JJ.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1500-1510. doi: 10.1158/1055-9965.EPI-16-0787. Epub 2017 Jul 14.

PMID:
28710075
20.

Treatment of cervical intraepithelial lesions.

Castle PE, Murokora D, Perez C, Alvarez M, Quek SC, Campbell C.

Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:20-25. doi: 10.1002/ijgo.12191. Review.

PMID:
28691333
21.

Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Cheung LC, Pan Q, Hyun N, Schiffman M, Fetterman B, Castle PE, Lorey T, Katki HA.

Stat Med. 2017 Sep 30;36(22):3583-3595. doi: 10.1002/sim.7380. Epub 2017 Jun 28.

PMID:
28660629
22.

Why does cervical cancer occur in a state-of-the-art screening program?

Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Schiffman M.

Gynecol Oncol. 2017 Sep;146(3):546-553. doi: 10.1016/j.ygyno.2017.06.003. Epub 2017 Jun 10.

PMID:
28606721
23.

Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer.

Burger EA, Kim JJ, Sy S, Castle PE.

Clin Infect Dis. 2017 Sep 15;65(6):893-899. doi: 10.1093/cid/cix475.

PMID:
28531261
24.

Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, Xie Y, Miachon LS, Dean M.

J Clin Microbiol. 2017 Aug;55(8):2348-2355. doi: 10.1128/JCM.00492-17. Epub 2017 May 17.

25.

Cervical cancer prevention in El Salvador (CAPE)-An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country.

Maza M, Alfaro K, Garai J, Velado MM, Gage JC, Castle PE, Felix J, Luciani S, Campos N, Kim J, Masch R, Cremer M.

Gynecol Oncol Rep. 2017 Mar 3;20:58-61. doi: 10.1016/j.gore.2017.02.011. eCollection 2017 May.

26.

Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines.

Schiffman M, Wentzensen N, Khan MJ, Castle PE, Chelmow D, Huh WK, Moscicki AB, Stockdale CK, Darragh TM, Silver M, Guido RS.

J Low Genit Tract Dis. 2017 Apr;21(2):87-90. doi: 10.1097/LGT.0000000000000300. No abstract available.

PMID:
28244885
27.

Screening to Prevent Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Castle PE, Jeronimo J, Temin S, Shastri SS.

J Clin Oncol. 2017 Apr 10;35(11):1250-1252. doi: 10.1200/JCO.2016.71.6563. Epub 2017 Jan 30. No abstract available.

PMID:
28135111
28.

Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador.

Cremer M, Maza M, Alfaro K, Morales Velado M, Felix J, Castle PE, Kim J, Gage JC.

J Low Genit Tract Dis. 2017 Jan;21(1):26-32. doi: 10.1097/LGT.0000000000000280.

29.

Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.

Engesæter B, van Diermen Hidle B, Hansen M, Moltu P, Staby KM, Borchgrevink-Persen S, Vintermyr OK, Lönnberg S, Nygård M, Janssen EA, Castle PE, Christiansen IK.

BMC Infect Dis. 2016 Nov 24;16(1):698.

30.

Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary.

Jeronimo J, Castle PE, Temin S, Shastri SS.

J Oncol Pract. 2017 Feb;13(2):129-133. doi: 10.1200/JOP.2016.017889. Epub 2016 Nov 15. No abstract available.

PMID:
27845871
31.

Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N, Kinney W, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Obstet Gynecol. 2016 Dec;128(6):1248-1257.

32.

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

Grant BD, Smith CA, Castle PE, Scheurer ME, Richards-Kortum R.

Vaccine. 2016 Nov 4;34(46):5656-5663. doi: 10.1016/j.vaccine.2016.09.021. Epub 2016 Sep 22.

33.

Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.

Castle PE, Aslam S, Behrens C.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1595-1599. Epub 2016 Sep 1.

34.

When Less is More.

Castle PE.

J Natl Cancer Inst. 2016 Oct 18;109(2). pii: djw240. Print 2017 Feb. No abstract available.

PMID:
27756809
35.

Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.

Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee JH, Du R, Robertson M, Norville S, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

JAMA Oncol. 2017 Jun 1;3(6):833-837. doi: 10.1001/jamaoncol.2016.3609.

36.

CK7 Immunohistochemistry as a Predictor of CIN1 Progression: A Retrospective Study of Patients From the Quadrivalent HPV Vaccine Trials.

Mills AM, Paquette C, Terzic T, Castle PE, Stoler MH.

Am J Surg Pathol. 2017 Feb;41(2):143-152. doi: 10.1097/PAS.0000000000000747.

PMID:
27680604
37.

The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.

Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, Lorey T, Kinney WK, Castle PE.

Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.

38.

HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.

Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C, Lazcano-Ponce E.

Salud Publica Mex. 2016 Apr;58(2):211-9.

39.

Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico.

McDonald YJ, Goldberg DW, Scarinci IC, Castle PE, Cuzick J, Robertson M, Wheeler CM.

J Rural Health. 2017 Sep;33(4):382-392. doi: 10.1111/jrh.12202. Epub 2016 Aug 24.

PMID:
27557124
40.

Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.

Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K.

Int J Cancer. 2016 Dec 15;139(12):2771-2780. doi: 10.1002/ijc.30392.

41.

A cohort study of cervical screening using partial HPV typing and cytology triage.

Schiffman M, Hyun N, Raine-Bennett TR, Katki H, Fetterman B, Gage JC, Cheung LC, Befano B, Poitras N, Lorey T, Castle PE, Wentzensen N.

Int J Cancer. 2016 Dec 1;139(11):2606-15. doi: 10.1002/ijc.30375. Epub 2016 Aug 26.

42.

Age of human papillomavirus vaccination?

Castle PE, Burger EA.

Lancet Infect Dis. 2016 Oct;16(10):1091-1093. doi: 10.1016/S1473-3099(16)30144-X. Epub 2016 Jun 28. No abstract available.

PMID:
27373899
43.

Time for a Model List of Essential Diagnostics.

Schroeder LF, Guarner J, Elbireer A, Castle PE, Amukele TK.

N Engl J Med. 2016 Jun 30;374(26):2511-4. doi: 10.1056/NEJMp1602825. No abstract available.

44.

Screening: A risk-based framework to decide who benefits from screening.

Castle PE, Katki HA.

Nat Rev Clin Oncol. 2016 Sep;13(9):531-2. doi: 10.1038/nrclinonc.2016.101. Epub 2016 Jun 21. No abstract available.

45.

HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women.

Mirabello L, Yeager M, Cullen M, Boland JF, Chen Z, Wentzensen N, Zhang X, Yu K, Yang Q, Mitchell J, Roberson D, Bass S, Xiao Y, Burdett L, Raine-Bennett T, Lorey T, Castle PE, Burk RD, Schiffman M.

J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw100. doi: 10.1093/jnci/djw100. Print 2016 Sep.

PMID:
27130930
46.

Prophylactic HPV vaccination: past, present, and future - CORRIGENDUM.

Castle PE, Maza M.

Epidemiol Infect. 2016 Aug;144(11):2472. doi: 10.1017/S0950268816000777. Epub 2016 Apr 29. No abstract available.

PMID:
27125301
47.

A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.

Khan MJ, Massad LS, Kinney W, Gold MA, Mayeaux EJ Jr, Darragh TM, Castle PE, Chelmow D, Lawson HW, Huh WK.

Gynecol Oncol. 2016 May;141(2):364-370. doi: 10.1016/j.ygyno.2015.11.023. Epub 2016 Feb 22. Review.

48.

A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results.

Khan MJ, Massad LS, Kinney W, Gold MA, Mayeaux EJ Jr, Darragh TM, Castle PE, Chelmow D, Lawson HW, Huh WK.

J Low Genit Tract Dis. 2016 Apr;20(2):119-25. doi: 10.1097/LGT.0000000000000185. Review.

PMID:
26901279
49.

Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador.

Cremer ML, Maza M, Alfaro KM, Kim JJ, Ditzian LR, Villalta S, Alonzo TA, Felix JC, Castle PE, Gage JC.

J Low Genit Tract Dis. 2016 Apr;20(2):145-50. doi: 10.1097/LGT.0000000000000188.

50.

Risk assessment to guide cervical screening strategies in a large Chinese population.

Zhao FH, Hu SY, Zhang Q, Zhang X, Pan QJ, Zhang WH, Gage JC, Wentzensen N, Castle PE, Qiao YL, Katki HA, Schiffman M.

Int J Cancer. 2016 Jun 1;138(11):2639-47. doi: 10.1002/ijc.30012. Epub 2016 Feb 4.

Supplemental Content

Loading ...
Support Center